RS Oncology Announces New Preclinical Data Show RSO-021 May Block and/or Reverse the Progression of Aggressive Mesotheliomas, Improving Druggability
13.9.2023 16:57:00 EEST | Business Wire | Press release
RS Oncology, a clinical stage biotechnology company developing innovative therapies to eradicate mesothelioma and other diseases, was part of a collaboration that recently shared new preclinical data at the IASLC 2023 World Conference on Lung Cancer in Singapore. The data, presented by Dr. Dean Fennell, represented a partnership between RS Oncology and other lead research institutions, including the University of Leicester and the Cunniff Laboratory at the University of Vermont Cancer Center.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230912702236/en/
“Sarcomatoid tumors are highly resistant to anti-cancer therapies, and many patients run out of available treatment options. Our findings here might have unveiled a druggable ‘Achilles Heel’ against this terrible disease,” said Dr. Fennell, presenting author on the study. Dr. Fennell and Dr. Cunniff shown at lunch during AACR conference 2023. (Photo courtesy of George Naumov)
Mesotheliomas can transform from a less aggressive epithelioid malignancy to a more aggressive sarcomatoid form. Using biphasic mesotheliomas as a model containing both epithelioid and sarcomatoid features, investigators at the University of Leicester, led by Dr. Fennell, conducted a geospatial analysis of patient tissues to explore the molecular signatures associated with the histological regions.
Using sophisticated spatial analysis tools coupled with machine learning approaches, the group found that the more aggressive sarcomatoid regions had distinct molecular signatures driving pro-tumor pathways, drug resistance, and increased metastatic potential. These findings were validated across an independent cohort of 150 mesothelioma patient tissues. Notably, tumor regions containing sarcomatoid tissue showed features of increased resistance to oxidative stress – a critical tumor cell adaptation for survival.
In collaboration with Dr. Brian Cunniff’s laboratory, the team then evaluated molecular signatures of human biphasic mesothelioma tumor cells following treatment with the irreversible PRX3 inhibitor RSO-021, which is currently being evaluated in a Phase 1/2 clinical trial in patients with malignant pleural effusion caused by advanced/metastatic solid tumors (NCT05278975). RSO-021 treatment reversed the gene signatures associated with epithelial-to-sarcomatoid transition, including downregulation of hypoxia, glycolysis, and epithelial-to-mesenchymal transition (EMT)-associated genes. These results suggest that this transition, thought to be unidirectional in nature, may be PRX3-dependent, druggable, and now reversible.
“Sarcomatoid tumors are highly resistant to anti-cancer therapies, and many patients run out of available treatment options. Our findings might have unveiled a druggable ‘Achilles Heel’ against this terrible disease,” said Dr. Fennell, presenting author on the study. “The ability to treat such tumors with RSO-021 and revert them to epithelioid malignancies could delay or even prevent emergence of the most aggressive features associated with mesothelioma. Further, RSO-021 could potentially sensitize them to other treatments.”
Presentation Details
Abstract Number: MA17.11
Session:
MA17 - Current Standards and Future Directions in Mesothelioma
Title: Spatial Transformation in Mesothelioma Involves a Hypoxia-TGF Beta-EMT Axis that is Reversible via PRX3 Inhibition
Date: Tuesday, September 12, 10:45 AM UTC +8
About RS Oncology
RS Oncology (RSO) is a clinical stage biotechnology company based in Cambridge, Massachusetts with a mission to eradicate mesothelioma and other diseases worldwide through novel science and an innovative business model.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912702236/en/
Contact information
Jarrett Duncan, CEO
j.duncan@rsoncology.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
teamLab Biovortex Kyoto to Open ' Teahouse in a Sea of Light ' for Savoring Tea. On View from Friday, November 20. Artworks Including Tea in Spontaneous Order on View20.11.2026 08:00:00 EET | Press release
teamLab Biovortex Kyoto opens ‘Teahouse in a Sea of Light’ on Friday, November 20, 2026, where visitors can savor tea within the Sea of Solidified Light. Artworks exhibited in the teahouse, including Tea in Spontaneous Order, are now unveiled. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117922442/en/ Aged Coffee Tonic, Tea in Spontaneous Order, 2021- ©︎ teamLab *Shot in real space. No AI or CGI. *No Artificial Colors Teahouse in a Sea of Light A space for savoring tea within a sea of light. When a cup of tea is made, the artwork is born. The tea interacts with nearby tea and the sea of light, creating a time structure throughout the entire space of the artwork. Visitors drink part of this formed order itself. Coinciding with the opening of ‘Teahouse in a Sea of Light,’ Pocket Garden of Eternal Existence is newly unveiled at the museum's entrance gate. teamLab Biovortex Kyoto teamLab Biovortex Kyoto is teamLab's largest
CORRECTING and REPLACING Visa Expands Agentic Ready to Help Scale Trusted AI Commerce Globally19.11.2026 23:11:00 EET | Press release
This announcement replaces the release dated November 17, 2026 with the following version: J.P. Morgan Payments was added to the subhead and after the 11th paragraph. Multimedia was also updated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117269823/en/ Visa Agentic Ready Acceptance Partners The updated release reads: VISA EXPANDS AGENTIC READY TO HELP SCALE TRUSTED AI COMMERCE GLOBALLY Adyen, Antom, Billtrust, Checkout.com, Fiserv, Global Payments, J.P. Morgan Payments, PayPal, Stripe along with over 140 initial participants join Agentic Ready program for acceptance ecosystem. Merchants, B2B suppliers, payment providers, acquirers and commerce platforms can now join the 175+ issuers already participating in Agentic Ready across 45 markets. Visa (NYSE: V), a world leader in digital payments, today announced the expansion of the Visa Agentic Ready program to the acceptance ecosystem. As a part of Visa Intelligent Commer
OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 18:30:00 EET | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac
ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 17:24:00 EET | Press release
When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technology risks, and ensure regulatory compliance. “Over the last 30 years, COBIT has been a trusted framework for countless organizations, providing a holistic, stru
North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 17:04:00 EET | Press release
North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioenergy with carbon capture and storage (BECCS) projects selected through the competitive process, following a r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
